Table 1.

Tumour and patients’ characteristics

Primary tumour, n (%)
Right-sided primary colon cancer (RSP)	10 (20)
Left-sided primary colon cancer (LSP)	29 (58)
Rectum cancer (LSP)	11 (22)
CEA increased	46 (92)
CA 19.9 increased	25 (50)
Primary tumour treatment, n (%)
Surgery	44 (88)
Radiochemotherapy	6 (12)
Systemic chemotherapy	13 (26)
Targeted therapy	6 (12)
Eastern Cooperative Oncology Group (ECOG) performance status, n (%)
0	36 (72)
1	11 (22)
2	3 (6)
Primary TNM status, n (%)
Tis	0	N0	6 (12)	M0	16 (32)
T1	5 (10)	N1a	11 (22)	M1	28 (56)
T2	5 (10)	N1b	8 (16)	Mx	4 (8)
T3	28 (56)	N1c	3 (6)
T4	10 (20)	N2a	5 (10)
		N2b	3 (6)
		Nx	12 (24)

Molecular characterisation
RAS, n (%)
Yes	17 (34)
No	24 (48)
N/A	9 (18)
BRAF, n (%)
Yes	5 (10)
No	18 (36)
N/A	27 (54)
Extrahepatic metastases
Yes, n (%)	16 (32)
No, n (%)	34 (68)
Median number (larger than 10 mm) (min, max)	2 (1,6)
Location, n (%)
Lymph nodes	5 (31)
Peritoneum	1 (6)
Lung	12 (75)
Bones	1 (6)
Liver metastases
Time since primary cancer diagnosis, n (%)
Median time for liver metastases since primary tumour diagnosis, years (min, max)	2 (0.3, 9.7)
Synchronous (< 6 months)	34 (68)
Metachronous (> 6 months)	16 (32)
Location, n (%)
Whole liver	26 (52)
Left liver lobe only	7 (14)
Right liver lobe only	17 (34)
Liver tumour burden, n (%)
< 25%	33 (66)
25–50%	13 (26)
> 50%	4 (8)
Median size of the two largest lesions, mm (min, max)
Lesion 1	54 (10, 132) × 43,5 (10, 127)
Lesion 2	30 (9, 94)  × 25 (8, 87)
Number of lesions, n (%)
1	8 (16)
2–3	16 (32)
4–10	15 (30)
> 10	11 (22)
Previous treatments for liver metastases, n (%)
Systemic chemotherapy	41 (82)
1 line	9 (18)
2 lines	6 (12)
3 or more lines	26 (52)
Anti-angiogenic targeted therapy	18 (36)
Anti-EGFR targeted therapy	10 (20)
Surgery	10 (20)
Adjuvant fluoropyrimidine	2 (4)
Adjuvant oxaliplatin	2 (4)
Adjuvant irinotecan	2 (4)
Ablation	5 (10)
Intra-arterial treatment	6 (12)